Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Halpern · SciRah

Researcher profile · Semantic Scholar

A. Halpern

Share profile

A. Halpern — researcher profile on SciRah

h-index: 17
Works: 152
Citations: 1,434

Most-cited papers

Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
R. Palmieri, M. Othus, A. Halpern, Mary-Elizabeth M. Percival +3 more
2020Journal of Clinical Oncology53 citations Open access
Semantic Scholar
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.
Mary-Elizabeth M. Percival, R. Lynch, A. Halpern, M. Shadman +12 more
2020JCO Oncology Practice24 citations Open access
Semantic Scholar
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms
Carla S. Walti, A. Halpern, Hu Xie, Erika S. Kiem +12 more
2022Leukemia18 citations Open access
Semantic Scholar
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
K. Pettit, H. Gill, A. Yacoub, T. Bradley +28 more
2022Blood14 citations Open access
Semantic Scholar
Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
Gabrielle Paras, M. Othus, Kelda G Schonhoff, C. Shaw +7 more
2022Leukemia13 citations Open access
Semantic Scholar
A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
H. Gill, F. Palandri, D. Ross, T. Cochrane +21 more
2022Blood13 citations Open access
Semantic Scholar
P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)
F. Palandri, D. Ross, T. Cochrane, C. Tate +24 more
2021HemaSphere12 citations Open access
Semantic Scholar
Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations
J. Goethert, H. Gill, F. Palandri, David M. Ross +16 more
2023Blood11 citations Open access
Semantic Scholar
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia
Kelsey-Leigh A Garcia, S. Cherian, P. Stevenson, C. Martino +10 more
2021Cancer11 citations
Semantic Scholar
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
Noam E. Kopmar, Kim Quach, T. Gooley, C. Martino +8 more
2024JAMA Oncology10 citations Open access
Semantic Scholar
Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samples
Suravi Raychaudhuri, H. Gem, Kevin Chung, Jeffrey S. McLean +11 more
2025npj Biofilms and Microbiomes9 citations Open access
Semantic Scholar
Time independent factors that predict relapse in adults with acute myeloid leukemia
John J Lim, M. Othus, C. Shaw, Kathryn Russell +6 more
2024Blood Cancer Journal9 citations Open access
Semantic Scholar
A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
N. Gangat, J. Foran, A. Halpern, R. Rampal +11 more
2024Blood9 citations
Semantic Scholar
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
A. Halpern, E. Rodríguez-Arbolí, M. Othus, Kelsey-Leigh A Garcia +13 more
2023Blood Advances8 citations Open access
Semantic Scholar
Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms
A. Halpern, M. Othus, N. P. Howard, P. Hendrie +10 more
2020Leukemia and Lymphoma7 citations
Semantic Scholar
Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation
E. Krakow, R. Walter, Julia M. Nathe, Tess Perez +6 more
2022American journal of hematology/oncology6 citations Open access
Semantic Scholar
Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy
A. Halpern, M. Othus, N. P. Howard, P. Hendrie +5 more
2021Leukemia and Lymphoma6 citations
Semantic Scholar
Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis
John Mascarenhas, J. Scandura, V. Gupta, Kazuya Shimoda +34 more
2025Blood5 citations
Semantic Scholar
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
J. Watts, A. Hunter, Alessandro Vannuchhi, V. Gupta +18 more
2024Blood5 citations
Semantic Scholar
A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
N. Gangat, J. Foran, A. Halpern, R. Rampal +5 more
2023Blood5 citations Open access
Semantic Scholar
Phase II Study of Dose-Adjusted EPOCH as Initial Therapy for Adults with High-Risk Acute Lymphoblastic Leukemia
R. Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, O. Sala-Torra +16 more
2023Leukemia and Lymphoma5 citations Open access
Semantic Scholar
Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis.
Nathan Moore, M. Othus, A. Halpern, N. P. Howard +8 more
2021The Journal of the National Comprehensive Cancer Network5 citations Open access
Semantic Scholar
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
Mary-Elizabeth M. Percival, M. Othus, Sarah Mirahsani, K. Gardner +7 more
2020Haematologica5 citations Open access
Semantic Scholar
Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia
Harinder Gill, F. Palandri, David M. Ross, J. Göthert +18 more
2026Blood Advances4 citations Open access
Semantic Scholar
Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia
Khushboo Pal, M. Othus, Z. Ali, Kathryn Russell +6 more
2024Blood Advances4 citations Open access
Semantic Scholar
Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
J. Watts, A. Vannucchi, A. Hunter, Brandon McMahon +14 more
2023Blood4 citations Open access
Semantic Scholar
Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms
J. Lindsay, Carla S. Walti, A. Halpern, Hu Xie +16 more
2023Blood Advances4 citations Open access
Semantic Scholar
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
L. Shih, M. Othus, Kelda G Schonhoff, C. Shaw +6 more
2023Leukemia4 citations Open access
Semantic Scholar
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Colin D. Godwin, E. Rodríguez-Arbolí, M. Othus, A. Halpern +10 more
2022Cancers4 citations Open access
Semantic Scholar
RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis.
N. Gangat, A. Tefferi, P. Bose, Elizabeth O. Hexner +13 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Care Patterns and Barriers to Outpatient Care for Adults With AML Following Intensive Chemotherapy at NCCN Member Institutions.
A. Halpern, Jessica Sugalski, Lindsey A. M. Bandini, M. Othus +2 more
2024The Journal of the National Comprehensive Cancer Network3 citations Open access
Semantic Scholar
Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia
Lucas C Zarling, P. Stevenson, Lorinda Soma, C. Martino +11 more
2023European Journal of Haematology3 citations
Semantic Scholar
Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
Piyanuch Kongtim, Mary-Elizabeth M. Percival, T. Martins, Guangrong Qin +14 more
2022Blood3 citations Open access
Semantic Scholar
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)
Michael J. Hochman, M. Othus, R. Walter, C. Shaw +6 more
2021Leukemia and Lymphoma3 citations
Semantic Scholar
Relation between measurable residual disease and morphologic relapse in AML.
L. Shih, M. Othus, K. Gardner, C. Shaw +5 more
20203 citations
Semantic Scholar
Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis
Kelsey-Leigh A Garcia, P. Stevenson, S. Cherian, Christen N. Martino +11 more
20203 citations
Semantic Scholar
Phase II Single Center Prospective Study of Ruxolitinib in Addition to Standard Graft Versus Host Disease Prophylaxis in Patients with Myelofibrosis Demonstrates Encouraging Outcomes.
Rachel B. Salit, Kevin Ng, Nellie Ratsamee, A. Halpern +4 more
2025Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar
Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
Noam E. Kopmar, Henry Le, Kim Quach, Ted A. Gooley +9 more
2024Blood2 citations
Semantic Scholar
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm
A. Halpern, M. Othus, Genevieve Alcorn, Z. Ali +7 more
2022Leukemia2 citations
Semantic Scholar
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study
Harinder Gill, Abdulraheem Yacoub, A. Gerds, J. Shortt +18 more
2026Blood Advances1 citations Open access
Semantic Scholar
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
D. Sallman, G. Garcia-Manero, Naval G. Daver, C. Abboud +22 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Pre-Hematopoietic Cell Transplant Ruxolitinib in Transplant-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study
Rachel B. Salit, Xinyi Fan, T. Gooley, A. Halpern +4 more
2025Transplantation and Cellular Therapy1 citations Open access
Semantic Scholar
Logistical and Non-Medical Barriers to Hematopoietic Cell Transplantation (HCT) and Chimeric Antigen Receptor T-Cell (CAR T) Therapy: A Survey of National Comprehensive Cancer Network (NCCN) Centers
Hannah R. Abrams, Helene Starks, Lindsey A. M. Bandini, Terry Harrington +6 more
2025Transplantation and Cellular Therapy1 citations Open access
Semantic Scholar
A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)
N. Gangat, A. Tefferi, A. Gerds, Mike R. Grunwald +17 more
2025Blood1 citations
Semantic Scholar
RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
N. Gangat, A. Tefferi, P. Bose, E. Hexner +13 more
2025Blood1 citations
Semantic Scholar
National Landscape of Logistical and Non-Medical Requirements for Transplantation and Cellular Therapy.
Hannah R. Abrams, Helene Starks, Lindsey A. M. Bandini, Terry Harrington +7 more
2025Transplantation and Cellular Therapy1 citations
Semantic Scholar
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.
J. Watts, A. Vannucchi, A. Hunter, Brandon McMahon +14 more
2024Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Evaluation of the toxicity and outcomes of the combination of midostaurin and CLAG-M in patients with FLT3-mutated acute myeloid leukemia (AML): A multi-center retrospective analysis.
Ashley Chen, Grace T. Baek, Shannon Palmer, Jack Rasmussen +9 more
2024Journal of Clinical Oncology1 citations
Semantic Scholar
CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
Filippo Milano, B. Sandmaier, Mary-Elizabeth M. Percival, Sarah M Mahan +8 more
2024Blood1 citations
Semantic Scholar
Evaluation of ECOG Performance Status at Diagnosis and Relapse in Patients with Acute Myeloid Leukemia
Michelle Y. Zhang, C. Shaw, Kathryn Russell, Rutu D. Vyas +5 more
2023Blood1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Mary-Elizabeth M. Percival×26
Invite
Mary-Elizabeth M. Percival — researcher profile on SciRah
R. Walter×18
Invite
R. Walter — researcher profile on SciRah
M. Othus×16
Invite
M. Othus — researcher profile on SciRah
E. Estey×16
Invite
E. Estey — researcher profile on SciRah

×13

Invite

P. Hendrie — researcher profile on SciRah

R. Cassaday×12

Invite

R. Cassaday — researcher profile on SciRah

Invite

P. Becker — researcher profile on SciRah

Invite

F. Palandri — researcher profile on SciRah

Invite

C. Shaw — researcher profile on SciRah

Jacob S Appelbaum×9

Invite

Jacob S Appelbaum — researcher profile on SciRah

A. Vannucchi×8

Invite

A. Vannucchi — researcher profile on SciRah

Invite

V. Oehler — researcher profile on SciRah